The abnormal aggregation of tau protein and neuronal damage are key processes in the onset and progression of neurodegenerative diseases, and treatment during the therapeutic window is of great importance for the effectiveness of tau protein-targeted therapy. The gene discussed is MAPT; the disease is neurodegenerative disease.